Cancer Advisor

Medically Reviewed | Last updated on May 30, 2026. Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fe...

Quick Summary (TL;DR) The American Society of Clinical Oncology (ASCO) has released an updated guideline on circulating tumor DNA (ctDNA) testing (often called a liquid biopsy ) for patients with solid tumors and lymphoma. This simple blood test can detect cancer DNA to help guide treatment. The guidelines recommend ctDNA testing when standard tissue biopsies are too risky, when quick decisions are required, or when a targeted drug demands it. However, because liquid biopsies can miss some mutations, a negative blood test should always be confirmed with a traditional tissue biopsy. Cancer care is rapidly shifting away from one-size-fits-all treatments toward highly personalized medicine. At the forefront of this revolution is a revolutionary blood test known as a liquid biopsy . To clear up confusion and set a gold standard for care, a multidisciplinary expert panel—which intentionally included dedicat...

Evidence review and hypothesis-generating biomarker framework Abstract Background: Fenbendazole is a benzimidazole anthelmintic used in veterinary medicine that has attracted interest as a potential repurposed anticancer compound. Preclinical studies have reported multiple biological effects, including disruption of microtubules, proteasome-associated stress, altered glucose utilization, effects on glycolysis, apoptosis, and changes in p53 signaling. However, fenbendazole is not an established human anticancer therapy, and human pharmacokinetic, efficacy, dosing, interaction, and safety data remain limited. Objective: To develop a molecularly stratified framework for evaluating potential fenbendazole sensitivity according to tumor genotype and phenotype, with particular attention to TP53 , MDM2 , MDM4/MDMX , KRAS , EGFR , MYC , BRAF , RB1 , CDKN2A , GLUT1 , and HK2 . Methods: Published experimental and clinical literature was reviewed with emphasis on mechanistic studie...